Changes in valuations of biopharma companies by extent 2020
In 2020, 39 percent of surveyed U.S. biopharma executives stated that company valuations increased by 10 percent to 20 percent; while 23 percent believed that valuations exceeded 20 percent. This statistic illustrates the changes in valuations of biopharmaceutical companies worldwide according to U.S. biopharma executives.